DK1776377T3 - Nyt steroid til FXR - Google Patents

Nyt steroid til FXR

Info

Publication number
DK1776377T3
DK1776377T3 DK05715596T DK05715596T DK1776377T3 DK 1776377 T3 DK1776377 T3 DK 1776377T3 DK 05715596 T DK05715596 T DK 05715596T DK 05715596 T DK05715596 T DK 05715596T DK 1776377 T3 DK1776377 T3 DK 1776377T3
Authority
DK
Denmark
Prior art keywords
fxr
new steroid
steroid
new
solvates
Prior art date
Application number
DK05715596T
Other languages
Danish (da)
English (en)
Inventor
Roberto Pellicciari
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1776377T3 publication Critical patent/DK1776377T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05715596T 2004-02-26 2005-02-28 Nyt steroid til FXR DK1776377T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04004408A EP1568706A1 (de) 2004-02-26 2004-02-26 Neuer Steroid-Agonist für FXR
PCT/EP2005/002086 WO2005082925A2 (en) 2004-02-26 2005-02-28 Novel steroid agonist for fxr

Publications (1)

Publication Number Publication Date
DK1776377T3 true DK1776377T3 (da) 2008-11-24

Family

ID=34745911

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05715596T DK1776377T3 (da) 2004-02-26 2005-02-28 Nyt steroid til FXR

Country Status (11)

Country Link
US (1) US7812011B2 (de)
EP (2) EP1568706A1 (de)
AT (1) ATE402945T1 (de)
CY (1) CY1108455T1 (de)
DE (1) DE602005008611D1 (de)
DK (1) DK1776377T3 (de)
ES (1) ES2313305T3 (de)
PL (1) PL1776377T3 (de)
PT (1) PT1776377E (de)
SI (1) SI1776377T1 (de)
WO (1) WO2005082925A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303399T1 (de) 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
PL1734970T3 (pl) 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN101522703B (zh) 2006-06-27 2013-04-17 英特塞普特医药品公司 胆酸派生物及其在制备预防或治疗fxr介导的疾病或状况的药物中的应用
EP1886685A1 (de) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors
JP5292310B2 (ja) 2007-01-19 2013-09-18 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５調節剤としての２３−置換胆汁酸およびその使用方法
US8338628B2 (en) * 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
ES2663948T3 (es) 2008-11-19 2018-04-17 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y método de uso de los mismos
US20110257139A1 (en) 2008-12-19 2011-10-20 Royal College Of Surgeons In Ireland Treatment of diarrhoea
EP2255813A1 (de) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Ursodeoxycholsäurederivate zur Behandlung von Diarrhöe
US8258485B2 (en) * 2010-08-30 2012-09-04 Media Lario Srl Source-collector module with GIC mirror and xenon liquid EUV LPP target system
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
PT3336097T (pt) * 2012-06-19 2020-10-29 Intercept Pharmaceuticals Inc Preparação da forma não cristalina de ácido obeticólico
HUE036887T2 (hu) 2012-10-26 2018-08-28 Intercept Pharmaceuticals Inc Eljárás epesav-származékok elõállítására
CA2912139C (en) * 2013-05-14 2021-04-20 Roberto Pellicciari 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
PL3043865T3 (pl) 2013-09-11 2021-07-05 Institut National De La Santé Et De La Recherche Médicale (Inserm) SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B
CA3236835A1 (en) 2013-11-22 2015-05-28 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
EP3626725B1 (de) * 2014-05-29 2022-11-30 Bar Pharmaceuticals S.r.l. Cholanderivate zur verwendung in der behandlung und/oder prävention von fxr- und tgr5/gpbar1-vermittelten krankheiten
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
EP3221333B1 (de) * 2014-11-19 2019-07-24 NZP UK Limited 6.alpha-alkyl-3,7-dionsteroide als zwischenprodukte zur herstellung von steroiden fxr-modulatoren
JP6698085B2 (ja) 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド
EA033445B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EP3221331B1 (de) 2014-11-19 2019-09-18 Nzp Uk Limited 6-alkyl-7-hydroxy-4-en-3-on-steroide als zwischenprodukte zur herstellung von steroidalen fxr-modulatoren
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
HK1244708A1 (zh) 2014-11-26 2018-08-17 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
TN2017000344A1 (en) 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
MX2017010376A (es) 2015-02-11 2017-12-20 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
WO2016161003A1 (en) 2015-03-31 2016-10-06 Enanta Phamraceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
CN105777836A (zh) * 2015-04-09 2016-07-20 厦门蔚扬药业有限公司 奥贝胆酸的多晶型物及其制备方法
TW201704251A (zh) * 2015-04-29 2017-02-01 正大天晴藥業集團股份有限公司 鵝去氧膽酸衍生物
EP3124080A1 (de) 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Semisynthetische gallsäurederivate zur injektionslipolyse
CN105175473B (zh) * 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN106632564B (zh) * 2015-10-30 2021-04-13 苏州泽璟生物制药股份有限公司 奥贝胆酸盐及其无定形物和药物组合物
CN106749466B (zh) * 2015-11-23 2019-05-21 南京济群医药科技股份有限公司 一种高纯度奥贝胆酸的制备方法
CN105315320B (zh) * 2015-11-30 2017-03-08 山东省药学科学院 一种制备奥贝胆酸的方法
CN106810586A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸晶型ⅱ及其制备方法和用途
CN106810587A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 制备无定型奥贝胆酸的方法
EP3409684B1 (de) 2016-01-28 2024-01-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Steroidderivat-fxr-agonist
US20170233431A1 (en) 2016-02-17 2017-08-17 City Of Hope Bile acid derivatives and methods for synthesis and use
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US11161871B2 (en) * 2016-03-31 2021-11-02 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of obeticholic acid and preparation method therefor
TW201738254A (zh) * 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
EA038580B9 (ru) * 2016-05-18 2021-10-05 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Агонист fxr, представляющий собой производное стероидов
WO2017207648A1 (en) 2016-05-31 2017-12-07 Bionice, S.L.U Process and intermediates for the preparation of obeticholic acid and derivatives thereof
CN108602850B (zh) * 2016-07-13 2021-04-06 江苏恒瑞医药股份有限公司 一种奥贝胆酸及其中间体的制备方法
CN110121347A (zh) 2016-11-29 2019-08-13 英安塔制药有限公司 制备磺酰脲胆汁酸衍生物的方法
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
AU2018223146B2 (en) 2017-02-21 2023-12-21 Genfit Combination of a PPAR agonist with a FXR agonist
WO2018165269A2 (en) * 2017-03-08 2018-09-13 Intercept Pharmaceuticals, Inc Crystalline forms of obeticholic acid
US20210085662A1 (en) 2017-03-30 2021-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
BR112019020780A2 (pt) 2017-04-07 2020-04-28 Enanta Pharm Inc processo para preparação de derivados de ácido biliar de carbamato de sulfonila
KR102725185B1 (ko) 2017-05-26 2024-11-01 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 Fxr 수용체 작용제로서 락탐 화합물
CN109021056B (zh) * 2017-06-09 2021-03-09 博瑞生物医药（苏州）股份有限公司 法尼酯x受体激动剂
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020039449A1 (en) 2018-08-24 2020-02-27 Solara Active Pharma Sciences Limited An improved process for the preparation of obeticholic acid and intermediates used in the process thereof
KR102889845B1 (ko) * 2018-11-26 2025-11-26 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 Fxr 작용제의 고체 형태, 결정 형태, 및 결정 형태 a, 및 이의 제조방법 및 이의 적용
EA202193334A1 (ru) 2019-05-30 2022-03-14 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
AU2020312735A1 (en) 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
US20230146782A1 (en) * 2019-08-06 2023-05-11 Du Jessica Xinyun Deoxycholic acid compounds, pharmaceutical compositions and uses thereof
US20230060715A1 (en) 2020-01-15 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
GB202416085D0 (en) 2024-10-31 2024-12-18 Nzp Uk Ltd Reduction process

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1223313B (it) * 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
US20050107475A1 (en) * 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici

Also Published As

Publication number Publication date
PL1776377T3 (pl) 2009-02-27
CY1108455T1 (el) 2014-04-09
SI1776377T1 (sl) 2009-04-30
DE602005008611D1 (de) 2008-09-11
ES2313305T3 (es) 2009-03-01
WO2005082925A3 (en) 2005-11-24
ATE402945T1 (de) 2008-08-15
EP1568706A1 (de) 2005-08-31
PT1776377E (pt) 2008-11-11
US20080039435A1 (en) 2008-02-14
EP1776377B1 (de) 2008-07-30
EP1776377A2 (de) 2007-04-25
WO2005082925A2 (en) 2005-09-09
US7812011B2 (en) 2010-10-12

Similar Documents

Publication Publication Date Title
CY1108455T1 (el) Νεος στεροειδης αγωνιστης δια fxr
DK1392714T3 (da) Steroider som agonister for FXR
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
CY1107368T1 (el) Νεα παραγωγα 4-βενζυλιδενο-πιπεριδινης
EA201070786A1 (ru) Бензофуропиримидиноны
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
DE602005023197D1 (de) -muscarinrezeptors
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
GEP20084494B (en) New heterocyclic carboxylic acid amide derivatives
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
ECSP034708A (es) Nueva sal de benzoilguanidina
EA200901085A1 (ru) Производные циклогексиламида арилкарбоновой кислоты
ATE496061T1 (de) Festphasenpeptidsynthese
TW200740756A (en) Potentiator of glutamate receptors
TW200740442A (en) Therapeutic agent for hypertension